Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018
The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza virus infection in Japan in February 2018. Two influenza A(H3N2) viruses carrying an I38T substitution in the polymerase acidic subunit (PA) were detected in baloxavir-treated children in De...
Saved in:
| Published in | Euro surveillance : bulletin européen sur les maladies transmissibles Vol. 24; no. 3; p. 1 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Sweden
Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS)
17.01.2019
European Centre for Disease Prevention and Control (ECDC) |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza virus infection in Japan in February 2018. Two influenza A(H3N2) viruses carrying an I38T substitution in the polymerase acidic subunit (PA) were detected in baloxavir-treated children in December 2018. This mutation is known to confer reduced susceptibility to baloxavir, and the two mutant viruses exhibited 76- and 120-fold reduced susceptibility to baloxavir. |
|---|---|
| AbstractList | The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza virus infection in Japan in February 2018. Two influenza A(H3N2) viruses carrying an I38T substitution in the polymerase acidic subunit (PA) were detected in baloxavir-treated children in December 2018. This mutation is known to confer reduced susceptibility to baloxavir, and the two mutant viruses exhibited 76- and 120-fold reduced susceptibility to baloxavir. The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza virus infection in Japan in February 2018. Two influenza A(H3N2) viruses carrying an I38T substitution in the polymerase acidic subunit (PA) were detected in baloxavir-treated children in December 2018. This mutation is known to confer reduced susceptibility to baloxavir, and the two mutant viruses exhibited 76- and 120-fold reduced susceptibility to baloxavir.The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza virus infection in Japan in February 2018. Two influenza A(H3N2) viruses carrying an I38T substitution in the polymerase acidic subunit (PA) were detected in baloxavir-treated children in December 2018. This mutation is known to confer reduced susceptibility to baloxavir, and the two mutant viruses exhibited 76- and 120-fold reduced susceptibility to baloxavir. |
| Author | Mitamura, Keiko Takashita, Emi Shirakura, Masayuki Kawakami, Chiharu Morita, Hiroko Watanabe, Shinji Miura, Hideka Kuwahara, Tomoko Ogawa, Rie Fujisaki, Seiichiro Nakamura, Kazuya Odagiri, Takato Abe, Takashi Kishida, Noriko Ichikawa, Masataka Yamazaki, Masahiko |
| Author_xml | – sequence: 1 givenname: Emi surname: Takashita fullname: Takashita, Emi organization: Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 2 givenname: Chiharu surname: Kawakami fullname: Kawakami, Chiharu organization: Yokohama City Institute of Public Health, Kanagawa, Japan – sequence: 3 givenname: Hiroko surname: Morita fullname: Morita, Hiroko organization: Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 4 givenname: Rie surname: Ogawa fullname: Ogawa, Rie organization: Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 5 givenname: Seiichiro surname: Fujisaki fullname: Fujisaki, Seiichiro organization: Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 6 givenname: Masayuki surname: Shirakura fullname: Shirakura, Masayuki organization: Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 7 givenname: Hideka surname: Miura fullname: Miura, Hideka organization: Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 8 givenname: Kazuya surname: Nakamura fullname: Nakamura, Kazuya organization: Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 9 givenname: Noriko surname: Kishida fullname: Kishida, Noriko organization: Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 10 givenname: Tomoko surname: Kuwahara fullname: Kuwahara, Tomoko organization: Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 11 givenname: Keiko surname: Mitamura fullname: Mitamura, Keiko organization: Eiju General Hospital, Tokyo, Japan – sequence: 12 givenname: Takashi surname: Abe fullname: Abe, Takashi organization: Abe Children’s Clinic, Kanagawa, Japan – sequence: 13 givenname: Masataka surname: Ichikawa fullname: Ichikawa, Masataka organization: Ichikawa Children’s Clinic, Kanagawa, Japan – sequence: 14 givenname: Masahiko surname: Yamazaki fullname: Yamazaki, Masahiko organization: Zama Children’s Clinic, Kanagawa, Japan – sequence: 15 givenname: Shinji surname: Watanabe fullname: Watanabe, Shinji organization: Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan – sequence: 16 givenname: Takato surname: Odagiri fullname: Odagiri, Takato organization: Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30670142$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkt1u1DAQhSNURH_gFZAlJFQkNtiOEyc3SFV3oaAKLgrXlu2Mu66ydrCdVcuz8LA4sCylV1yNZR99c8ZzjosD5x0UxUuCS9pi_obUDV7wjvBydVVSTLqSsrIqSYtx07WPiqO94ODe-bA4jvEGY1bhjj4pDivccEwYPSp-LCGBTtY75A2yzgwTuO8SnZ1eVJ_oK7S1YYoQEdyurbLJumsUoJ809ChOUcOY8vVg0x1KHqU1IOe3MCAtx0UPI7geXEK5eDfpAWSE3OMXyQek5OBvZe6Q79BHOUr3Gi1Bw0ZBQHm29mnx2MghwrNdPSm-vlt9Ob9YXH5-_-H87HKh64qmBTQN50b1pq1lZVrOKOl6RTqueG9qgwGDolAbo03Xc6aoblSneiJb01bQ6OqkePubO05qA73OnoMcxBjsRoY74aUV_744uxbXfiuairGWkQw43QGC_zZBTGJj8-cMg3Tgpygo4R1jDDdtlr54IL3xU3B5vFmFMxCzOque33e0t_JncX8t6-BjDGD2EoLFnBQxL1_MyxerKzEnRVAmKrFLSgYsHwC0TXIOQp7QDv-L-Ql6F8o8 |
| CitedBy_id | crossref_primary_10_1542_peds_2021_053745 crossref_primary_10_2147_IJGM_S273266 crossref_primary_10_1016_j_antiviral_2020_104828 crossref_primary_10_1016_j_antiviral_2021_105158 crossref_primary_10_1016_j_antiviral_2023_105635 crossref_primary_10_1016_j_antiviral_2024_105956 crossref_primary_10_1007_s00705_022_05456_0 crossref_primary_10_1016_S1473_3099_23_00743_0 crossref_primary_10_1016_j_antiviral_2020_104782 crossref_primary_10_1111_petr_13645 crossref_primary_10_1111_tid_13542 crossref_primary_10_54097_e3g0fk77 crossref_primary_10_2807_1560_7917_ES_2019_24_12_1900170 crossref_primary_10_3390_ijms232012244 crossref_primary_10_1128_JVI_02149_19 crossref_primary_10_3390_v12020167 crossref_primary_10_3389_fphar_2019_01203 crossref_primary_10_1002_bmc_5388 crossref_primary_10_1101_cshperspect_a038687 crossref_primary_10_1016_j_biopha_2022_113780 crossref_primary_10_1016_j_antiviral_2020_104951 crossref_primary_10_1016_j_antiviral_2019_104545 crossref_primary_10_1007_s40265_020_01350_8 crossref_primary_10_1038_s41467_023_41442_z crossref_primary_10_1080_22221751_2020_1742076 crossref_primary_10_1186_s12879_023_08140_z crossref_primary_10_1542_peds_2022_059275 crossref_primary_10_3389_fmed_2019_00109 crossref_primary_10_7883_yoken_JJID_2019_210 crossref_primary_10_1002_2211_5463_13416 crossref_primary_10_1002_iid3_984 crossref_primary_10_1093_infdis_jiaa061 crossref_primary_10_1016_j_idcr_2019_e00650 crossref_primary_10_1093_infdis_jiab196 crossref_primary_10_1016_j_virol_2020_02_005 crossref_primary_10_1007_s00705_023_05958_5 crossref_primary_10_1186_s44149_023_00100_z crossref_primary_10_1038_s12276_021_00603_0 crossref_primary_10_3390_applmicrobiol2030037 crossref_primary_10_3390_medicina59091543 crossref_primary_10_1038_s41591_022_01908_x crossref_primary_10_1016_j_chaos_2023_113199 crossref_primary_10_1038_s42003_020_0952_y crossref_primary_10_1111_irv_12728 crossref_primary_10_1016_j_resinv_2020_06_003 crossref_primary_10_1007_s11030_023_10659_x crossref_primary_10_1261_rna_078951_121 crossref_primary_10_1625_jcam_19_23 crossref_primary_10_1073_pnas_1916825117 crossref_primary_10_2147_CPAA_S268666 crossref_primary_10_3390_pharmaceutics15061732 crossref_primary_10_3390_v11111066 crossref_primary_10_1016_j_antiviral_2020_104881 crossref_primary_10_1093_infdis_jiz418 crossref_primary_10_1038_s41467_024_49161_9 crossref_primary_10_1542_peds_2019_2478 crossref_primary_10_1371_journal_ppat_1008395 crossref_primary_10_1080_14728214_2022_2149734 crossref_primary_10_1038_s41598_019_40937_4 crossref_primary_10_1097_MCP_0000000000000667 crossref_primary_10_1016_j_bmc_2021_116515 crossref_primary_10_1093_cid_ciz908 crossref_primary_10_1101_cshperspect_a038463 crossref_primary_10_1099_jgv_0_001325 crossref_primary_10_4155_fmc_2021_0264 crossref_primary_10_1016_j_bsheal_2020_04_004 crossref_primary_10_1093_infdis_jiaa164 crossref_primary_10_1111_irv_12721 crossref_primary_10_3389_fmicb_2021_611958 crossref_primary_10_1016_j_resinv_2019_10_005 crossref_primary_10_1200_JOP_19_00144 crossref_primary_10_3201_eid2511_190757 crossref_primary_10_3390_v15010244 crossref_primary_10_1016_j_trsl_2020_01_005 crossref_primary_10_3390_v15051154 crossref_primary_10_3389_fphar_2021_633292 |
| Cites_doi | 10.1111/irv.12446 10.1056/NEJMoa1716197 10.1038/s41598-018-27890-4 10.3389/fmicb.2018.03026 10.1177/135965350701200S04.1 |
| ContentType | Journal Article |
| Copyright | Copyright Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS) Jan 17, 2019 This article is copyright of the authors or their affiliated institutions, 2019. 2019 The authors or their affiliated institutions |
| Copyright_xml | – notice: Copyright Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS) Jan 17, 2019 – notice: This article is copyright of the authors or their affiliated institutions, 2019. 2019 The authors or their affiliated institutions |
| CorporateAuthor | on behalf of the Influenza Virus Surveillance Group of Japan |
| CorporateAuthor_xml | – name: on behalf of the Influenza Virus Surveillance Group of Japan |
| DBID | AAYXX CITATION NPM 7X8 5PM |
| DOI | 10.2807/1560-7917.ES.2019.24.3.1800698 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Public Health |
| EISSN | 1560-7917 |
| ExternalDocumentID | PMC6344841 30670142 10_2807_1560_7917_ES_2019_24_3_1800698 |
| Genre | Journal Article |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GroupedDBID | --- 2WC 53G 5GY 5VS 9K5 AAYXX ABOCM ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK E3Z EBD EBS EJD EMOBN F5P FRP GROUPED_DOAJ GX1 HYE IPNFZ KQ8 M48 OK1 OVT P6G PQQKQ RIG RNS RPM SV3 TR2 XSB ADRAZ FZ- NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c532t-e6677fbdf85a3f874219db197b7df5f0e0eb2e5ffcf9d74b2c6b9bd1a8f83e6c3 |
| IEDL.DBID | M48 |
| ISSN | 1560-7917 1025-496X |
| IngestDate | Thu Aug 21 18:18:34 EDT 2025 Fri Jul 11 00:29:30 EDT 2025 Mon Jun 30 03:54:31 EDT 2025 Mon Jul 21 05:49:32 EDT 2025 Tue Jul 01 01:59:04 EDT 2025 Thu Apr 24 23:07:10 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | cap-dependent endonuclease inhibitor resistant baloxavir marboxil Influenza virus baloxavir acid |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c532t-e6677fbdf85a3f874219db197b7df5f0e0eb2e5ffcf9d74b2c6b9bd1a8f83e6c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Correspondence: Takato Odagiri (todagiri@nih.go.jp) |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.2807/1560-7917.ES.2019.24.3.1800698 |
| PMID | 30670142 |
| PQID | 2170344045 |
| PQPubID | 105456 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6344841 proquest_miscellaneous_2179444068 proquest_journals_2170344045 pubmed_primary_30670142 crossref_primary_10_2807_1560_7917_ES_2019_24_3_1800698 crossref_citationtrail_10_2807_1560_7917_ES_2019_24_3_1800698 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-01-17 |
| PublicationDateYYYYMMDD | 2019-01-17 |
| PublicationDate_xml | – month: 01 year: 2019 text: 2019-01-17 day: 17 |
| PublicationDecade | 2010 |
| PublicationPlace | Sweden |
| PublicationPlace_xml | – name: Sweden – name: Saint-Maurice |
| PublicationTitle | Euro surveillance : bulletin européen sur les maladies transmissibles |
| PublicationTitleAlternate | Euro Surveill |
| PublicationYear | 2019 |
| Publisher | Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS) European Centre for Disease Prevention and Control (ECDC) |
| Publisher_xml | – name: Centre Europeen pour la Surveillance Epidemiologique du SIDA (European Centre for the Epidemiological Monitoring of AIDS) – name: European Centre for Disease Prevention and Control (ECDC) |
| References | Omoto (r3) 2018; 8 (r8) 2012; 87 r6 r7 Aoki (r5) 2007; 12 Takashita (r4) 2018; 9 Hayden (r2) 2018; 379 Koszalka (r1) 2017; 11 |
| References_xml | – volume: 11 start-page: 240 issue: 3 year: 2017 ident: r1 article-title: Influenza antivirals currently in late-phase clinical trial. publication-title: Influenza Other Respir Viruses doi: 10.1111/irv.12446 – volume: 87 start-page: 369 issue: 39 year: 2012 ident: r8 article-title: Meetings of the WHO working group on surveillance of influenza antiviral susceptibility – Geneva, November 2011 and June 2012. publication-title: Wkly Epidemiol Rec – ident: r6 – ident: r7 – volume: 379 start-page: 913 issue: 10 year: 2018 ident: r2 article-title: Baloxavir marboxil for uncomplicated influenza in adults and adolescents. publication-title: N Engl J Med doi: 10.1056/NEJMoa1716197 – volume: 8 start-page: 9633 issue: 1 year: 2018 ident: r3 article-title: Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. publication-title: Sci Rep doi: 10.1038/s41598-018-27890-4 – volume: 9 start-page: 3026 issue: 3026 year: 2018 ident: r4 article-title: Susceptibility of influenza viruses to the novel cap-dependent endonuclease inhibitor baloxavir marboxil. publication-title: Front Microbiol doi: 10.3389/fmicb.2018.03026 – volume: 12 start-page: 603 year: 2007 ident: r5 article-title: Influenza virus susceptibility and resistance to oseltamivir. publication-title: Antivir Ther doi: 10.1177/135965350701200S04.1 |
| SSID | ssj0043092 |
| Score | 2.4970412 |
| Snippet | The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza virus infection in Japan in February 2018. Two... |
| SourceID | pubmedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1 |
| SubjectTerms | Disease control Drug therapy Influenza Medical treatment Rapid Communication |
| Title | Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018 |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30670142 https://www.proquest.com/docview/2170344045 https://www.proquest.com/docview/2179444068 https://pubmed.ncbi.nlm.nih.gov/PMC6344841 |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1La9wwEBZpCqVQQt_dNA0qlNJC7fohW9IhlNBsWALJJV3ITciyRBcWO7W9Ielv6Y_tjOw13baHvVoeja2RmBlp9H2EvLNCRgzcdCATFwWMMRtoCEwCIXmmnSly4clgzi_y2ZydXWVXO2R9hWAYwPa_qR3ySc2bZXj74-4LLPgjLGMWEf-Ml4ERdpGH00ss1pJhwsI0jAXC8Ip75D54KY7sBudsPGFgaeQJk0fZB-T9dv1tOrB_otK_iyv_8Fanj8neEGbS435ePCE7tnpKHvV7dLS_evSM_Dqxna_Eqmjt6KKnK_mp6fGHWXqRfKQ3i2bV2pZaJNFeYH00bRDp1Za0XbW-HsaX1t7RrqYQSNKqvrFLavR1sObW7ahFuhAETQZ3CTp8T3VDC72sbzVogGf0DDx29YmeWGORn4TCaIjnZH46_fZ1FgxsDYHJ0qQLbJ5z7orSiUynTkDKHcuyiCUveOkyF9kIknibOWecLDkrEpMXsihjLZxIbW7SF2S3qiv7ilAT4xVYVqIEy3gBIZMsc-0sN5B9Gj0hR2sTKDNAmSOjxlJBSoMmVGhChSZU00uFJlQJU6kaTDghfJS_7kE9tpY8WFtcreeqgqwOgRMhOJ6Qt2MzLFM8e9GVrVf-HQkrIcqhi5f9BBlVY9YGmWoCn7UxdcYXEAJ8s6VafPdQ4DnoFSze30Lva_IQfwe3j2J-QHa7ZmXfQEDVFYd-I-LQr4_fvNIZrA |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Detection+of+influenza+A%28H3N2%29+viruses+exhibiting+reduced+susceptibility+to+the+novel+cap-dependent+endonuclease+inhibitor+baloxavir+in+Japan%2C+December+2018&rft.jtitle=Euro+surveillance+%3A+bulletin+europ%C3%A9en+sur+les+maladies+transmissibles&rft.au=Takashita%2C+Emi&rft.au=Kawakami%2C+Chiharu&rft.au=Morita%2C+Hiroko&rft.au=Ogawa%2C+Rie&rft.date=2019-01-17&rft.issn=1560-7917&rft.eissn=1560-7917&rft.volume=24&rft.issue=3&rft_id=info:doi/10.2807%2F1560-7917.ES.2019.24.3.1800698&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1560-7917&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1560-7917&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1560-7917&client=summon |